1.60
price up icon2.56%   0.04
after-market After Hours: 1.60
loading
Inflarx N V stock is traded at $1.60, with a volume of 63,867. It is up +2.56% in the last 24 hours and up +2.56% over the past month. InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.56
Open:
$1.53
24h Volume:
63,867
Relative Volume:
0.90
Market Cap:
$90.68M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-2.1425
EPS:
-0.7468
Net Cash Flow:
$-41.02M
1W Performance:
+2.24%
1M Performance:
+2.56%
6M Performance:
+15.94%
1Y Performance:
+15.94%
1-Day Range:
Value
$1.52
$1.60
1-Week Range:
Value
$1.49
$1.60
52-Week Range:
Value
$1.14
$2.10

Inflarx N V Stock (IFRX) Company Profile

Name
Name
Inflarx N V
Name
Phone
-
Name
Address
-
Name
Employee
66
Name
Twitter
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
IFRX's Discussions on Twitter

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-05-23 Upgrade Guggenheim Neutral → Buy
Feb-28-22 Downgrade Guggenheim Buy → Neutral
Oct-28-21 Upgrade Raymond James Outperform → Strong Buy
Mar-11-21 Upgrade Guggenheim Neutral → Buy
Nov-06-20 Upgrade SVB Leerink Mkt Perform → Outperform
Oct-08-20 Initiated H.C. Wainwright Buy
Jun-17-20 Initiated BTIG Research Buy
Apr-30-20 Upgrade Raymond James Mkt Perform → Outperform
Jun-05-19 Downgrade BMO Capital Markets Outperform → Market Perform
Jun-05-19 Downgrade Guggenheim Buy → Neutral
Jun-05-19 Downgrade JP Morgan Overweight → Underweight
Jun-05-19 Downgrade Robert W. Baird Outperform → Neutral
Jun-05-19 Downgrade SunTrust Buy → Hold
Jan-29-19 Initiated Robert W. Baird Outperform
Dec-10-18 Initiated Credit Suisse Outperform
Jul-13-18 Initiated BMO Capital Markets Outperform
Jun-28-18 Initiated Raymond James Outperform
Jun-28-18 Initiated SunTrust Buy
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Inflarx N V Stock (IFRX) Latest News

pulisher
Nov 01, 2024

InflaRx (IFRX) Set to Announce Quarterly Earnings on Friday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

InflaRx to Report Third Quarter 2024 Financial Results on - GlobeNewswire

Oct 31, 2024
pulisher
Oct 14, 2024

InflaRx (NASDAQ:IFRX) Sees Significant Increase in Short Interest - MarketBeat

Oct 14, 2024
pulisher
Sep 26, 2024

InflaRx shares maintain Buy rating from H.C. Wainwright on Gohibic trial analysis - Investing.com

Sep 26, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress - Investing.com India

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx presents e-poster presentation of post hoc analysis of SHINE study - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 - EIN News

Sep 25, 2024
pulisher
Sep 25, 2024

InflaRx reports promising HS treatment results at EADV Congress By Investing.com - Investing.com Australia

Sep 25, 2024
pulisher
Sep 05, 2024

InflaRx Announces Participation in September Investor Events - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Stock Price Up 1.3% - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

InflaRx (NASDAQ:IFRX) Shares Up 1.3% - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human - EIN News

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx reports promising data on oral C5aR inhibitor INF904 By Investing.com - Investing.com UK

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx presents new preclinical findings for INF904 - TipRanks

Sep 03, 2024
pulisher
Sep 03, 2024

InflaRx Presents New Preclinical Findings for INF904 at the - GlobeNewswire

Sep 03, 2024
pulisher
Sep 01, 2024

InflaRx (NASDAQ:IFRX) Short Interest Down 9.2% in August - MarketBeat

Sep 01, 2024
pulisher
Aug 13, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 281.4% - MarketBeat

Aug 13, 2024
pulisher
Aug 08, 2024

InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx N.V. Reports Mid-Year Financial Results - TipRanks

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Aug 08, 2024
pulisher
Aug 08, 2024

InflaRx reports Q2 EPS (24c), consensus (22c) - TipRanks

Aug 08, 2024
pulisher
Aug 07, 2024

InflaRx (IFRX) Set to Announce Earnings on Thursday - Defense World

Aug 07, 2024
pulisher
Aug 02, 2024

InflaRx (IFRX) to Release Earnings on Thursday - MarketBeat

Aug 02, 2024
pulisher
Aug 01, 2024

InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewswire

Aug 01, 2024
pulisher
Jul 30, 2024

InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewswire

Jul 30, 2024
pulisher
Jul 15, 2024

Vasculitis Treatment Market with Tremendous growth by 2031 – Glaxosmithkline plc, Amneal Pharmaceuticals, Inc., ChemoCentryx, InflaRx N.V – TIMC - TIMC

Jul 15, 2024
pulisher
Jul 14, 2024

InflaRx (NASDAQ:IFRX) Short Interest Up 151.1% in June - American Banking and Market News

Jul 14, 2024
pulisher
Jul 12, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Expands By 151.1% - MarketBeat

Jul 12, 2024
pulisher
Jul 12, 2024

Short Interest in InflaRx (NASDAQ:IFRX) Rises By 151.1% - Defense World

Jul 12, 2024
pulisher
Jun 28, 2024

InflaRx Announces $75M Share Sales Agreement - TipRanks

Jun 28, 2024
pulisher
Jun 28, 2024

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia

Jun 28, 2024
pulisher
Jun 28, 2024

InflaRx (NASDAQ:IFRX) Short Interest Update - MarketBeat

Jun 28, 2024
pulisher
Jun 27, 2024

What Kind Of Investors Own Most Of InflaRx N.V. (NASDAQ:IFRX)? - Yahoo New Zealand News

Jun 27, 2024
pulisher
Jun 26, 2024

SEC Form 424B5 filed by InflaRx N.V. - Quantisnow

Jun 26, 2024
pulisher
Jun 25, 2024

InflaRx (NASDAQ:IFRX) Receives “Buy” Rating from HC Wainwright - Defense World

Jun 25, 2024
pulisher
Jun 24, 2024

InflaRx's ARDS drug selected for BARDA Phase 2 study - Investing.com India

Jun 24, 2024
pulisher
Jun 24, 2024

Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com

Jun 24, 2024
pulisher
Jun 24, 2024

Iron Mountain executive sells over $547k in company stock By Investing.com - Investing.com UK

Jun 24, 2024
pulisher
Jun 24, 2024

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed ... - WICZ

Jun 24, 2024
pulisher
Jun 24, 2024

InflaRx's GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire

Jun 24, 2024
pulisher
Jun 24, 2024

InflaRx’s GOHIBIC (Vilobelimab) Selected for First - GlobeNewswire

Jun 24, 2024
pulisher
Jun 07, 2024

InflaRx's (IFRX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jun 07, 2024
pulisher
Jun 06, 2024

InflaRx's (IFRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Jun 06, 2024
pulisher
Jun 05, 2024

InflaRx Hosts R&D Event Highlighting the Promise of INF904 - GlobeNewswire

Jun 05, 2024
pulisher
Jun 03, 2024

InflaRx (NASDAQ:IFRX) Trading Up 10.5% - MarketBeat

Jun 03, 2024

Inflarx N V Stock (IFRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):